Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
CD73 overexpression
i
Other names:
CD73, 5'-Nucleotidase Ecto, Ecto-5'-Nucleotidase, 5'-Nucleotidase, 5'-NT, NT5, NTE, 5'-Nucleotidase, Ecto (CD73), Purine 5-Prime-Nucleotidase, 5' Nucleotidase (CD73), CD73 Antigen, E5NT
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
CD73 overexpression
Non Small Cell Lung Cancer
CD73 overexpression
Non Small Cell Lung Cancer
durvalumab
Sensitive: D – Preclinical
AACR 2023 - 2 weeks (New D)
durvalumab
Sensitive
:
D
AACR 2023 - 2wk
durvalumab
Sensitive: D – Preclinical
AACR 2023 - 2 weeks
durvalumab
Sensitive
:
D
AACR 2023 - 2 weeks - (New D)
CD73 overexpression
Melanoma
CD73 overexpression
Melanoma
pembrolizumab
Resistant: C3 – Early Trials
pembrolizumab
Resistant
:
C3
pembrolizumab
Resistant: C3 – Early Trials
pembrolizumab
Resistant
:
C3
CD73 overexpression
Melanoma
CD73 overexpression
Melanoma
nivolumab
Resistant: C3 – Early Trials
nivolumab
Resistant
:
C3
nivolumab
Resistant: C3 – Early Trials
nivolumab
Resistant
:
C3
CD73 overexpression
Colorectal Cancer
CD73 overexpression
Colorectal Cancer
cetuximab
Sensitive: C3 – Early Trials
cetuximab
Sensitive
:
C3
cetuximab
Sensitive: C3 – Early Trials
cetuximab
Sensitive
:
C3
CD73 overexpression
Gastric Cancer
CD73 overexpression
Gastric Cancer
pembrolizumab
Resistant: C3 – Early Trials
pembrolizumab
Resistant
:
C3
pembrolizumab
Resistant: C3 – Early Trials
pembrolizumab
Resistant
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login